Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Shroom family member 2 (SHROOM2)
- Target
- SHROOM2
- Molecular classification
- cytoskeletal regulator, scaffolding protein
01
Overview
Shroom family member 2 (SHROOM2, also known as APXL and Shrm2) is a cytoskeletal scaffolding protein widely expressed in epithelial and various organ tissues including the nasal cavity, brain, retina, heart, lung, liver, and kidney. It contains a PDZ domain and two Shroom-specific domains (ASD1 and ASD2) that mediate interactions with actin and Rho-associated kinase (ROCK). SHROOM2 controls cell shape by organizing the actomyosin network at the plasma membrane, regulating the distribution of cytoskeletal components, and antagonizing the epithelial-mesenchymal transition implicated in migration and metastasis. Although mapped to a region associated with ocular albinism, SHROOM2 is not functionally involved in this disorder and is recognized for its role in epithelial cell architecture and migration. Unlike receptors or enzymes, SHROOM2 is a structural protein, not directly druggable, and currently has no established biomarkers or therapeutic indications.
- Other names
- APXLhShroom2Shrm2
02
Biological functions
Cell morphology regulationCytoskeletal organizationActomyosin network assemblyCell migrationMaintenance of epithelial architectureAntagonist for epithelial-mesenchymal transition (EMT)Stress fiber formationVasculogenesisMelanosome biogenesis
03
Disease associations
Metastasis (cancer cell migration/invasion)Vasculogenesis-related disordersOcular albinism (disputed/was considered due to mapping; not a causative factor)Potential role in epithelial cancers and tissue remodeling
Beyond the preview
Go deeper on Shroom family member 2 (SHROOM2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shroom family member 2 (SHROOM2).